




RealRate

PHARMACEUTICAL 2013

Talpera INC
Rank 165 of 218

AcelRx
Pharmaceuticals, Inc.



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Talpheria INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Talpheria INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 6.1% points. The greatest weakness of Talpheria INC is the variable Net Income, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is 130%, being 90% points below the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	61,766
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,331
Liabilities, Non-Current	8,530
Other Assets	269
Other Compr. Net Income	1.0
Other Expenses	7,722
Other Liabilities	7,812
Other Net Income	4,517
Other Revenues	0
Property and Equipment	2,485
Research and Development	92,329
Selling, General and Administrative Expense	26,493

Output Variable	Value in 1000 USD
Assets	64,520
Liabilities	30,673
Expenses	126,544
Revenues	0
Stockholders Equity	33,847
Net Income	-122,027
Comprehensive Net Income	-122,026
BaseVar	113,128
ECR before LimitedLiability	-101%
Economic Capital Ratio	130%